Table 3.
Changes in signs and symptoms of psoriasis between baseline and week 24
| Baseline | Week 24 | p value | |
|---|---|---|---|
| Characteristic (n = 18) | |||
| PASI (median, IQR) | 6.9 (3.5, 18.6) | 0.4 (0, 1.5) | 0.002** |
| BSA% (median, IQR) | 10.9 (3.6, 20.3) | 0.2 (0, 1.8) | 0.003** |
| DLQI (median, IQR) | 10 (5, 15) | 1.5 (0.75, 5.75) | 0.003** |
| VAS pain (median, IQR) | 18.5 (11.75, 49.5) | 7 (1, 14) | 0.003** |
| VAS global (median, IQR) | 68 (45, 74) | 8 (2.5, 26) | < 0.001** |
| VAS physician (median, IQR) | 35.5 (8.75, 62.75) | 7 (1, 15) | 0.011* |
| TJC 78 (median, IQR) (mean ± SD)† | 0 (0, 3.75); 2.65 ± 5.11 | 0 (0, 2); 0.63 ± 1.17 | 0.102 |
| PsAID (median, IQR) | 3.5 (1.65, 1.7) | 1.35 (0.2, 2.35) | 0.003** |
| Characteristic (n = 15) | |||
| PASI (median, IQR) | 6.9 (3.3, 15.4) | 0.3 (0, 1.1) | 0.007** |
| BSA% (median, IQR) | 9.2 (4.3, 18.1) | 0.05 (0, 1) | 0.013* |
| DLQI (median, IQR) | 12 (6.75, 15.75) | 2 (0.75, 8.25) | 0.013* |
| VAS pain (median, IQR) | 26 (14, 50) | 4 (1, 23) | 0.004** |
| VAS global (median, IQR) | 70 (61, 75) | 12 (1, 38) | 0.001** |
| VAS physician (median, IQR) | 37 (7, 50) | 4 (1, 22) | 0.036* |
| TJC 78 (median, IQR) (mean ± SD)† | 1 (0, 4); 3.53 ± 5.67 | 0 (0, 2); 0.53 ± 0.92 | 0.038* |
| PsAID (median, IQR) | 3.7 (2.84, 6.01) | 1.45 (0.25, 3.2) | 0.005** |
Data on the upper half are based on 18 psoriasis patients with complete baseline and 24-week data. Data on the lower half are based on patients with active joint inflammation in MRI at baseline (n = 15)
TJC tender joint count, VAS visual analogue scale, PASI psoriasis area and severity index, BSA% percent body surface area, IQR interquartile range, DLQI dermatology life quality index, PsAID psoriatic arthritis impact of disease
†Additionally reported as mean and standard deviation (mean ± SD) because median was equal to zero
Wilcoxon signed-rank test. *p ≤ 0.05, **p ≤ 0.01